Multiple Roles of the Tuberous Sclerosis Complex Genes

Genes Chromosomes and Cancer

Volumn 38, Issue 4, 2003, Pages 368-375

  Yeung, Raymond S ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; HAMARTIN; POLYCYSTIN; RAPAMYCIN; TUBERIN; WNT PROTEIN;

BIOCHEMISTRY; BIOLOGICAL MODEL; CANCER GENETICS; CANCER GROWTH; CARCINOGENESIS; CELL COMMUNICATION; CELL PROLIFERATION; CELL ULTRASTRUCTURE; COLON CANCER; COLON TUMOR; GENE FUNCTION; HETEROZYGOSITY LOSS; HUMAN; HYPOTHESIS; KIDNEY CARCINOMA; MELANOMA; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS; TUBEROUS SCLEROSIS COMPLEX 1 GENE; TUBEROUS SCLEROSIS COMPLEX 2 GENE; TUMOR; TUMOR SUPPRESSOR GENE; VALIDATION PROCESS;

ANIMALS; DISEASE MODELS, ANIMAL; GENES, TUMOR SUPPRESSOR; HUMANS; MODELS, GENETIC; PROTEINS; REPRESSOR PROTEINS; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 0344155285     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.10256     Document Type: Review

References (75)

1. Aicher LD, Campbell JS, Yeung RS. 2001. Tuberin phosphorylation regulates its interaction with hamartin. Two proteins involved in tuberous sclerosis. J Biol Chem 276:21017-21021.
2. Astrinidis A, Cash TP, Hunter DS, Walker CL, Chernoff J, Henske EP. 2002. Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene 21:8470-8476.
3. Benvenuto G, Li S, Brown SJ, Braverman R, Vass WC, Cheadle JP, Halley DJ, Sampson JR, Wienecke R, DeClue JE. 2000. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 19:6306-6316.
4. Bourneville DM. 1880. Sclérose tubéreuse des circonvolutions cérébrales: idiotie et épilepsie hémiplégique. Arch Neurol (Paris) 1:81-91.
5. Calastretti A, Rancati F, Ceriani MC, Asnaghi L, Canti G, Nicolin A. 2001. Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect. Eur J Cancer 37:2121-2128.
6. Capelluto DG, Kutateladze TG, Habas R, Finkielstein CV, He X, Overduin M. 2002. The DIX domain targets dishevelled to actin stress fibres and vesicular membranes. Nature 419:726-729.
7. Carbonara C, Longa L, Grosso E, Mazzucco G, Borrone C, Garre ML, Brisigotti M, Filippi A, Scabar A, Giannotti P, Falzoni G, Monga G, Garini M, Gabrielli P, Riegler G, Danesino C, Ruggieri M, Magro G, Migone N. 1996. Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas. Genes Chromosomes Cancer 15:18-25.
8. Crino PB, Henske EP. 1999. New developments in the neurobiology of the tuberous sclerosis complex. Neurology 53:1384-1390.
9. Crino PB, Trojanowski JQ, Dichter MA, Eberwine J. 1996. Embryonic neuronal markers in tuberous sclerosis: single-cell molecular pathology. Proc Natl Acad Sci USA 93:14152-14157.
10. Dan HC, Sun M, Yang L, Feldman RI, Sui XM, Ou CC, Nellist M, Yeung RS, Halley DJ, Nicosia SV, Pledger WJ, Cheng JQ. 2002. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 277:35364-35370.
11. Dancey JE. 2002. Clinical development of mammalian target of rapamycin inhibitors. Hematol Oncol Clin North Am 16:1101-1114.
12. Eker R, Mossige J, Johannessen JV, Aars H. 1981. Hereditary renal adenomas and adenocarcinomas in rats. Diagn Histopathol 4:99-110.
13. European Chromosome 16 Tuberous Sclerosis Consortium. 1993. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75:1305-1315.
14. Fukumoto S, Hsieh CM, Maemura K, Layne MD, Yet SF, Lee KH, Matsui T, Rosenzweig A, Taylor WG, Rubin JS, Perrella MA, Lee ME. 2001. Akt participation in the Wnt signaling pathway through Dishevelled. J Biol Chem 276:17479-17483.
15. Galbiati F, Volonte D, Engelman JA, Watanabe G, Burk R, Pestell RG, Lisanti MP. 1998. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J 17:6633-6648.
16. Galbiati F, Volonte D, Brown AM, Weinstein DE, Ben-Ze'ev A, Pestell RG, Lisanti MP. 2000. Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting beta-catenin to caveolae membrane domains. J Biol Chem 275:23368-23377.
17. Gao X, Zhang Y, Arrazola P, Hino O, Kobayashi T, Yeung RS, Ru B, Pan D. 2002. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol 4:699-704.
18. Gomez MR. 1999. Definition and criteria for diagnosis. In: Gomez MR, Sampson JR, Whittemore VH, editors. Tuberous sclerosis complex. New York: Oxford University Press.
19. Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, Yeung RS, Walker CL, Noonan D, Kwiatkowski DJ, Chou MM, Panettieri RA Jr, Krymskaya VP. 2002. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem 277:30958-30967.
20. Green AJ, Johnson PH, Yates JR. 1994. The tuberous sclerosis gene on chromosome 9q34 acts as a growth suppressor. Hum Mol Genet 3:1833-1834.
21. Haddad LA, Smith N, Bowser M, Niida Y, Murthy V, Gonzalez-Agosti C, Ramesh V. 2002. The TSC1 tumor suppressor hamartin interacts with neurofilament-L and possibly functions as a novel integrator of the neuronal cytoskeleton. J Biol Chem 277:44180-44186.
22. Henske EP, Scheithauer BW, Short MP, Wollmann R, Nahmias J, Hornigold N, van Slegtenhorst M, Welsh CT, Kwiatkowski DJ. 1996. Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet 59:400-406.
23. Hodges AK, Li S, Maynard J, Parry L, Braverman R, Cheadle JP, DeClue JE, Sampson JR. 2001. Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin. Hum Mol Genet 10:2899-2905.
24. Inoki K, Li Y, Zhu T, Wu J, Guan KL. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4:648-657.
25. Jaeschke A, Hartkamp J, Saitoh M, Roworth W, Nobukuni T, Hodges A, Sampson J, Thomas G, Lamb R. 2002. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J Cell Biol 159:217-224.
26. Jin F, Wienecke R, Xiao GH, Maize JC Jr, DeClue JE, Yeung RS. 1996. Suppression of tumorigenicity by the wild-type tuberous sclerosis 2 (Tsc2) gene and its C-terminal region. Proc Natl Acad Sci USA 93:9154-9159.
27. Karbowniczek M, Astrindis A, Balsara BR, Testa JR, Lium JH, Colby TV, McCormack FX, Henske EP. 2002. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 167:976-982.
28. Kenerson HL, Aicher LD, True LD, Yeung RS. 2002. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 62:5645-5650.
29. Kleymenova E, Ibraghimov-Beskrovnaya O, Kugoh H, Everitt J, Xu H, Kiguchi K, Landes G, Harris P, Walker C. 2001. Tuberin-dependent membrane localization of polycystin-1: a functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. Mol Cell 7:823-832.
30. Kobayashi T, Hirayama Y, Kobayashi E, Kubo Y, Hino O. 1995. A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer [published erratum appears in Nat Genet 1995 Feb9(2):218]. Nat Genet 9:70-74.
31. Kobayashi T, Hirayama Y, Kobayashi E, Kubo Y, Hino O. 1995. A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer [published erratum appears in Nat Genet 1995 Feb9(2):218]. Nat Genet 9:70-74.
32. 2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet 16:279-283.
33. Lamb RF, Roy C, Diefenbach TJ, Vinters HV, Johnson MW, Jay DG, Hall A. 2000. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol 2:281-287.
34. Li Y, Inoki K, Yeung R, Guan KL. 2002. Regulation of TSC2 by 14-3-3 binding. J Biol Chem 277:44593-44596.
35. Li Y, Inoki K, Vacratsis P, Guan KL. 2003. The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 (TSC2) gene product, and enhances its interaction with 14-3-3. J Biol Chem 278:13663-13671.
36. Liu MY, Cai S, Espejo A, Bedford MT, Walker CL. 2002. 14-3-3 interacts with the tumor suppressor tuberin at Akt phosphorylation site(s). Cancer Res 62:6475-6480.
37. Liu MY, Poellinger L, Walker CL. 2003. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Cancer Res 63:2675-2680.
38. Mak BC, Takemaru K, Kenerson HL, Moon RT, Yeung RS. 2003. The tuberin-hamartin complex negatively regulates beta-catenin signaling activity. J Biol Chem 278:5947-5951.
39. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10:151-162.
40. McManus EJ, Alessi DR. 2002. TSC1-TSC2: a complex tale of PKB-mediated S6K regulation. Nat Cell Biol 4:E214-E216.
41. 2+ pathways. Oncogene 18:7860-7872.
42. Moon RT, Bowerman B, Boutros M, Perrimon N. 2002. The promise and perils of Wnt signaling through beta-catenin. Science 296:1644-1646.
43. Nellist M, Verhaaf B, Goedbloed MA, Reuser AJ, van den Ouweland AM, Halley DJ. 2001. TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex. Hum Mol Genet 10:2889-2898.
44. Nellist M, Goedbloed MA, De Winter C, Verhaaf B, Jankie A, Reuser AJ, Van Den Ouweland AM, Van Der Sluijs P, Halley DJ. 2002. Identification and characterization of the interaction between tuberin and 14-3-3zeta. J Biol Chem 9:9.
45. Nguyen-Vu PA, Fackler I, Rust A, DeClue JE, Sander CA, Volkenandt M, Flaig M, Yeung RS, Wienecke R. 2001. Loss of tuberin, the tuberous-sclerosis-complex-2 gene product is associated with angiogenesis. J Cutan Pathol 28:470-475.
46. Noonan DJ, Lou D, Griffith N, Vanaman TC. 2002. A calmodulin binding site in the tuberous sclerosis 2 gene product is essential for regulation of transcription events and is altered by mutations linked to tuberous sclerosis and lymphangioleiomyomatosis. Arch Biochem Biophys 398:132-140.
47. Pandur P, Maurus D, Kuhl M. 2002. Increasingly complex: new players enter the Wnt signaling network. Bioessays 24:881-884.
48. Parrott LA, Templeton DJ. 1999. Osmotic stress inhibits p70/85 S6 kinase through activation of a protein phosphatase. J Biol Chem 274:24731-24736.
49. Patel J, McLeod LE, Vries RG, Flynn A, Wang X, Proud CG. 2002. Cellular stresses profoundly inhibit protein synthesis and modulate the states of phosphorylation of multiple translation factors. Eur J Biochem 269:3076-3085.
50. Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J, Dedhar S. 2000. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA 97:3207-3212.
51. Plas DR, Thompson CB. 2003. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem 278: 12361-12366.
52. Potter CJ, Pedraza LG, Xu T. 2002. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 4:658-665.
53. Povelones M, Nusse R. 2002. Wnt signalling sees spots. Nat Cell Biol 4:E249-E250.
54. Razandi M, Oh P, Pedram A, Schnitzer J, Levin ER. 2002. ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. Mol Endocrinol 16:100-115.
55. Rohde J, Heitman J, Cardenas ME. 2001. The TOR kinases link nutrient sensing to cell growth. J Biol Chem 276:9583-9586.
56. Saucedo LJ, Gao X, Chiarelli DA, Li L, Pan D, Edgar BA. 2003. Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat Cell Biol 5:566-571.
57. Schlegel A, Wang C, Katzenellenbogen BS, Pestell RG, Lisanti MP. 1999. Caveolin-1 potentiates estrogen receptor alpha (ERalpha) signaling. Caveolin-I drives ligand-independent nuclear translocation and activation of ERalpha. J Biol Chem 274:33551-33556.
58. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A. 1999. The cyclin DI gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96: 5522-5527.
59. Shumway SD, Li Y, Xiong Y. 2003. 14-3-3beta binds to and negatively regulates the tuberous sclerosis complex 2 (TSC2) tumor suppressor gene product, tuberin. J Biol Chem 278:2089-2092.
60. Simons K, Toomre D. 2000. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 1:31-39.
61. Smart EJ, Graf GA, McNiven MA, Sessa WC, Engelman JA, Scherer PE, Okamoto T, Lisanti MP. 1999. Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol 19:7289-7304.
62. Soucek T, Pusch O, Wienecke R, DeClue JE, Hengstschlager M. 1997. Role of the tuberous sclerosis gene-2 product in cell cycle control. Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase. J Biol Chem 272:29301-29308.
63. Stocker H, Hafen E. 2000. Genetic control of cell size. Curr Opin Genet Dev 10:529-535.
64. Stocker H, Radimerski T, Schindelholz B, Wittwer F, Belawat P, Daram P, Breuer S, Thomas G, Hafen E. 2003. Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat Cell Biol 5:559-566.
65. Tan C, Costello P, Sanghera J, Dominguez D, Baulida J, de Herreros AG, Dedhar S. 2001. Inhibition of integrin linked kinase (ILK) suppresses beta-catenin-Lef/Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in APC-/- human colon carcinoma cells. Oncogene 20:133-140.
66. Tetsu O, McCormick F. 1999. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422-426.
67. van Slegtenhorst M, de Hoogt R, Hermans C. Nellist M, Janssen B, Verhoef S, Lindhout D, van den Ouweland A, Halley D, Young J, Burley M, Jeremiah S, Woodward K, Nahmias J, Fox M, Ekong R, Osborne J, Wolfe J, Povey S, Snell RG, Cheadle JP, Jones AC, Tachataki M, Ravine D, Kwiatkowski DJ. 1997. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277:805-808.
68. Watson RT, Pessin JE. 2001. Subcellular compartmentalization and trafficking of the insulin-responsive glucose transporter, GLUT4. Exp Cell Res 271:75-83.
69. Xiao GH, Jin F, Yeung RS. 1995. Germ-line Tsc2 mutation in a dominantly inherited cancer model defines a novel family of rat intracisternal-A particle elements. Oncogene 11:81-87.
70. Xiao GH, Shoarinejad F, Jin F, Golemis EA, Yeung RS. 1997. The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis. J Biol Chem 272:6097-6100.
71. Yamamoto Y, Jones KA, Mak BC, Muehlenbachs A, Yeung RS. 2002. Multicompartmental distribution of the tuberous sclerosis gene products, hamartin and tuberin. Arch Biochem Biophys 404:210-217.
72. Yeung RS, Buetow KH, Testa JR, Knudson AG Jr. 1993. Susceptibility to renal carcinoma in the Eker rat involves a tumor suppressor gene on chromosome 10. Proc Natl Acad Sci USA 90:8038-8042.
73. Yeung RS, Xiao GH, Jin F, Lee WC, Testa JR, Knudson AG. 1994. Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc Natl Acad Sci USA 91:11413-11416.
74. Yeung RS, Xiao GH, Everitt JI, Jin F, Walker CL. 1995. Allelic loss at the tuberous sclerosis 2 locus in spontaneous tumors in the Eker rat. Mol Carcinog 14:28-36.
75. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. 2003. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5:578-581.